# Adcirca® (tadalafil) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tadalafil

> The FDA approved Adcirca® (tadalafil), sponsored by Sanofi (SNY), on September 30, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Adcirca® (tadalafil) FDA approved?

Yes. The FDA approved Adcirca® (tadalafil), sponsored by Sanofi (SNY), on September 30, 2024. SEC Form 10-Q: "During the nine months ended September 30, 2024, the Company became aware of a new competitor that received approval by the FDA for a combined finasteride-tadalafil capsule, which is a direct competitor product to ENTADFI." [Calendar and source filings](https://sec-api.dev/pdufa/tadalafil)

Source: SEC Form 10-Q, accession 0001213900-25-110142, https://www.sec.gov/Archives/edgar/data/1782107/000121390025110142/ea0264964-10q_onconetix.htm (retrieved 2026-11-12). Last confirmed 2025-11-13. Cite: https://sec-api.dev/pdufa/tadalafil#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Adcirca® (tadalafil) |
| Codes |  |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | Erectile Dysfunction |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Sep 2022: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-04-08, last confirmed 2025-07-16.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-029639): "It received FDA approval in September 2022." https://www.sec.gov/Archives/edgar/data/1782107/000121390025029639/ea023747101ex99-1_oncon.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-064469): "It received FDA approval in September 2022." https://www.sec.gov/Archives/edgar/data/1782107/000121390025064469/ea024881501ex99-1_oncone.htm

### March 31, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2024-12-10, last confirmed 2025-06-12.
- SEC Form 10-Q (accession 0001213900-25-053914): "During the three months ended March 31, 2024, the Company became aware of a new competitor that received approval by the FDA for a combined finasteride-tadalafil capsule, which is a direct competitor product to ENTADFI." https://www.sec.gov/Archives/edgar/data/1782107/000121390025053914/ea0245287-10q_onconetix.htm
- SEC Form 10-K (accession 0001213900-25-049687): "During the three months ended March 31, 2024, the Company became aware of a new competitor that received approval by the FDA for a combined finasteride-tadalafil capsule, which is a direct competitor product to ENTADFI." https://www.sec.gov/Archives/edgar/data/1782107/000121390025049687/ea0244122-10k_onconetix.htm
- SEC Form 10-Q (accession 0001213900-24-107088): "During the three months ended March 31, 2024, the Company became aware of a new competitor that received approval by the FDA for a combined finasteride-tadalafil capsule, which is a direct competitor product to ENTADFI." https://www.sec.gov/Archives/edgar/data/1782107/000121390024107088/ea0223979-10q_onconetix.htm

### September 30, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-11-13, last confirmed 2025-11-13.
- SEC Form 10-Q (accession 0001213900-25-110142): "During the nine months ended September 30, 2024, the Company became aware of a new competitor that received approval by the FDA for a combined finasteride-tadalafil capsule, which is a direct competitor product to ENTADFI." https://www.sec.gov/Archives/edgar/data/1782107/000121390025110142/ea0264964-10q_onconetix.htm

### March 2, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Erectile Dysfunction.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06805513 (Actual Use Trial of Tadalafil 5 mg): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-02 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06805513

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tadalafil.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Adcirca® (tadalafil) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tadalafil

```bibtex
@misc{secapidev_pdufa_tadalafil_20261116,
  title        = {Adcirca® (tadalafil) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tadalafil}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tadalafil_20261116","title":"Adcirca® (tadalafil) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tadalafil","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
